Skip to main content
OpenTrials
Completed

NCT Number: NCT06023797

Neoadjuvant Immunochemotherapy for Lung Cancer

We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhencong Chen

Shanghai, Shanghai Municipality, 200032, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Lung surgery was performed in the Department of Thoracic Surgery at Zhongshan Hospital;
  • At least one cycle of neoadjuvant treatment containing the immune drug PD-1 immunosuppressant was performed before surgery;
  • Malignancy was present and confirmed in the pathology before treatment and after surgery;
  • The lung lesion was the primary lesion.

Exclusion criteria

  • No lung surgery was performed until 2022.11;
  • No preoperative neoadjuvant therapy was performed or recorded;
  • Neoadjuvant therapy did not include immune drugs;
  • Previous history of malignancy (including surgery and adjuvant therapy);
  • Previous use of system-related immune medicines, such as immunosuppressants and monoclonal antibodies; and 6. Other conditions inappropriate for enrollment by the investigator.

Treatment and study plan

Neoadjuvant immunochemotherapy

Drug

Patients who received NAICT and were operated at the Department of Thoracic Surgery, Zhongshan Hospital Fudan University between 2017 and 2022.

Other names: surgery

Primary outcomes

  1. Progression-free survival (PFS)

    Time frame: 2017-2023

    Progression-free defined as status of recurrence of lung cancer

  2. Overall survival (OS)

    Time frame: 2017-2023

    Overall defined as the living status, alive or dead

Sponsors and collaborators

Lead sponsor

Shanghai Zhongshan Hospital

Other

Registry information

Official study title

Retrospective Research on Lung Cancer Patients Receiving Neoadjuvant Immunochemotherapy From Zhongshan Hospital Fudan University.

Important dates

Study start
2017
Primary completion
2022
Study completion
2023
First posted
Sep 5, 2023
Registry last updated
Sep 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.